MAJESTY Findings: Obinutuzumab in Primary Membranous Nephropathy

Roche reported that its phase III MAJESTY trial in adults with primary membranous nephropathy met the primary endpoint, with statistically significant results at two years (week 104) favoring obinutuzumab versus tacrolimus for complete remission.

MAJESTY was a global phase III, randomized, open-label, multicenter study that enrolled 142 adults and assigned participants 1:1 to receive obinutuzumab or tacrolimus.

On efficacy, significantly more people achieved complete remission at two years (week 104) with obinutuzumab than with tacrolimus. Roche also reported statistically significant findings for obinutuzumab versus tacrolimus on key secondary endpoints, including overall remission (complete or partial remission) at week 104 and complete remission at week 76. No new safety signals were identified in MAJESTY.